All News
Drug Naming Games (2.7.2025)
Dr. Jack Cush reviews the news, regulatory and journal reports from the past week on RheumNow.com.
Read Article
Granzyme - a major driver of inflammatory & autoimmune diseases
d
EurekAlert!
Our immune system is armed with an array of defenses designed to detect and eliminate harmful threats. One of its most powerful defense mechanisms is the complement system—a group of proteins that patrols our body, ever vigilant for signs of infection or injury.
Read Article
Cannabis Hospitalizations and Mortality Risk
A Canadian population, retrospective cohort study shows individuals needing hospital-based (emergency department or hospitalization) care for a cannabis use disorder (CUD) were at increased risk of death.
Read Article
Can #AI help us determine the
👇
Right drug
At
Right time
Pipe dream?
Or to use #artificial #intelligence term
➡️ a #hallucination?
garbage in ➡️➡️garbage out
Most predictions of drug response are same: multimorbid multiRx failures
Nonadherent poverty #RNL25 @RheumNow https://t.co/70SRp8BnCl
Janet Pope Janetbirdope ( View Tweet)
#RNL2025 is underway! https://t.co/VDEvK70Qg5
Dr. John Cush RheumNow ( View Tweet)
Such an important topic from @UnaMakris . The intersection of aging with our rheumatic disease processes is a crucial area. @RheumNow @RNL2025 https://t.co/n0Kx559g9e
Richard Conway RichardPAConway ( View Tweet)
Are your patients aging with RA, or are they diagnosed with Late Onset RA (LORA)?
-LORA pts tend to present acutely
-High inflammatory markers~PMR Like
-Seronegative/Decreased titers of RF/CCP
@UnaMakris
#RNL2025 @RheumNow https://t.co/aOCwb3lHef
Adela Castro AdelaCastro222 ( View Tweet)
J Curtis #RNL2025 @RheumNow
AI Will Not Replace You
- AI cannot replace human interaction, examination, procedures, interpreting guidelines for an individual, providing empathy, and facilitate good patient education
Will become a tool... but not a replacement to a good clinician https://t.co/qPcNOjWepi
Eric Dein ericdeinmd ( View Tweet)
AI is here to stay! It should be our ally in optimizing patient care and efficiency at work.
Here are the 10 commandments of AI from an amazing lecture from @RADoctor at #RNL2025 #AI #Rheumatology @RheumNow https://t.co/6BajZxGkwe
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Is Rheumatoid Arthritis Becoming Milder?
A 24 year, prospective study analyzing very early rheumatoid arthritis (RA) in three consecutive eras suggests that RA has evolved since 2005, demonstrating less seropositivity, inflammation, and erosions but is characterized by more… https://t.co/y50uCU79i9 https://t.co/crKytLY4WN
Dr. John Cush RheumNow ( View Tweet)
Pain Management in Rheumatoid Arthritis
BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.… https://t.co/1rcTxpQxxT https://t.co/s20bg5FJqQ
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - New Palmoplantar Psoriasis and PsA
New Onset Palmoplantar PsO and PsA - what are the options?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/3ubBL6HVGF https://t.co/Zdd6Dih5eZ
Links:
Dr. John Cush RheumNow ( View Tweet)
Facing challenges in diagnosing idiopathic inflammatory myopathies? Check out our recent webinar to hear from Stanley J. Naides, MD, FACP, FACR, as he explores the role of autoantibody testing in autoimmune myositis diagnosis and phenotyping. Sponsored by LabCorp Rx. #Myositis… https://t.co/4jMevolO3k https://t.co/ObWPR8QFW2
Dr. John Cush RheumNow ( View Tweet)
TNF inhibitor use did not affect mortality outcomes in 3 cohorts w/ early Cancer (colorectal [514], lung [864], & prostate [603]). 12-20% of CA pts recv TNFi. Overall survival at Yr 1 unaffected in colorectal (HR 0·72; 0·43–1·21), Lung (0·70; 0·49–1·00), Prostate (0·80;… https://t.co/Pi8rNuvioO
Dr. John Cush RheumNow ( View Tweet)
Rituximab is FDA approved for treatment of moderate to severe pemphigus, but 20% may relapse in 1st Yr. Study of 87 pts shows the efficacy of repeat 6 mos RTX in A) those with persistent Dz activity and B) anyone w/ predictors of relapse (PDAI score, DSG1 or DSG3 abs)… https://t.co/IhqdGWVcdp https://t.co/MKhDpa5zHv
Dr. John Cush RheumNow ( View Tweet)
BSR Guideline on Management of Sjögren disease
The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease.
https://t.co/UJOvb937lk https://t.co/P77h91nPuN
Dr. John Cush RheumNow ( View Tweet)
Overweight & obesity increase risk of Chr. Inflammatory Dz (CIDs). TriNetX EHR study of >3.1 million persons shows risk of any CID=28.5% in overweight/obese vs. 17.6% in controls (HR 1.52). Overweight/obesity posed a > risk of 4 CIDs in females & also >risk for 7 CIDs in Whites… https://t.co/U5ydFGolIY https://t.co/b3Jpl27wLf
Dr. John Cush RheumNow ( View Tweet)
Recent Excess Mortality in Young Adults
JAMA has published a University of Minnesota cross-sectional study showing early adult (ages 25-44) mortality in the U.S. has risen substantially between 2011 to 2019 and 2020 to 2023. The largest portion of 2023 excess mortality was… https://t.co/0LIoMqPkDj https://t.co/Ta5DU6aWfs
Dr. John Cush RheumNow ( View Tweet)
Is IL-23i better than IL-17i at lowering PsA risk? Retrospective, real-world EHR data study from TriNetX shows that among 4580 adult psoriasis pts (2,273 on IL23i vs 2,307 on IL17i), IL23i had signif lower PsA incidence (HR 0.60; 0.44–0.82, P 0.001), esp if 41-65 yrs (HR 0.42) &… https://t.co/ZuCAiOTIke https://t.co/8PkDCugYy0
Dr. John Cush RheumNow ( View Tweet)
QD Clinic - dsDNA without Lupus
Insufficient Sxs to Dx SLE, but persistent dsDNA positivity - what to do?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6… https://t.co/ov8THqrPyC https://t.co/jmtqxcWzJ0
Links:
Dr. John Cush RheumNow ( View Tweet)